Hera News & Events


OncoRat® featured in Clinical Cancer Research for prostate cancer studies

Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems: A case [...]

The OncoRat® is the ideal host for patient-derived xenografts of ovarian cancer cells

Ovarian cancer is the most lethal gynecological cancer in the [...]

Evolution of the rat model

Rats have been favored for drug development studies because the [...]

H358 NSCLC xenografts in humanized rats: the ideal in vivo model for studying KRAS mutations

Lung adenocarcinomas, the major histological subtype of non-small cell lung [...]

Hera Biolabs announces Molecular Cancer Therapeutics publication on immunodeficient rats for oncology research

Hera Biolabs, the University of Michigan, Case Western Reverse University [...]

By |October 19th, 2018|

Breakthroughs in gene editing allows for the creation of superior preclinical oncology models

Gene editing is getting a lot of attention in the [...]

The OncoRat®: Hosting valuable tumor xenograft models that are difficult or impossible to study using in vitro or mouse models

One of the most widely used methods of modeling human [...]

By |September 18th, 2018|

Patient derived xenograft studies from wider varieties of patient sub-populations promise improved clinical trial selection and design

Around 85% of preclinical drugs entering clinical trials in oncology [...]

By |August 9th, 2018|

OncoRat® PDX models highlighted in Drug Discovery News (DDN) Special Report on Cancer: Aiming for Avatars

While advances in in-vitro platforms have allowed researchers to better [...]

By |July 18th, 2018|

Hera Biolabs to present at the 2018 AACR Annual Meeting.

Hera Biolabs will be presenting xenograft, PDX, and humanization of [...]

By |April 12th, 2018|